explore -WSS

explore

author：comprehensive 2025-10-01 00:52:26 - browse：29

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： With psoriasis trial ahead, Alumis raises $259 million

WSS

Amylyx ALS drug failure raises questions and concerns

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Change Healthcare payments predicted restored March 15

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

entertainment

explore

focus

Cancer drug shortages should be causing more outrage

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

Trump demands the U.S. pay no more for drugs than other countries … again

US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans

How to save PrEP access — and even expand it

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Hepatitis C has a cure — but many Americans still lack access to it

RSV shot was 90% effective at preventing hospitalizations in kids

United colonoscopy coverage change 'may cost lives,' doctors say

NEJM study link tiny plastics in blood vessels to heart problems

leisure time

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

RSV shot was 90% effective at preventing hospitalizations in kids

Churchill Downs extends trainer Bob Baffert's ban through 2024

Some in Scotland's Orkney Islands want to return to Norway after 550 years

First medicine developed to treat MASH expected to be approved soon

entertainment

knowledge

focus

hotspot